VTYX - VTYX STOCKHOLDER NEWS: Contact Robbins LLP for Information Regarding the Ventyx Biosciences Inc. Class Action | Benzinga
SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all those who purchased or otherwise acquired Ventyx Biosciences, Inc. (NASDAQ:VTYX) (1) pursuant to the Offering Documents issued in connection with the Company's October 2021 initial public offering ("IPO") or (2) Ventyx securities between October 21, 2021 and November 6, 2023. Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases. The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. In 2022, Ventyx initiated a Phase 2 clinical trial of VTX958 for the treatment of moderate to severe plaque psoriasis (the "Phase 2 SERENITY Trial").
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Ventyx Biosciences, Inc. (VTYX) Allegedly Misled Investors Regarding the Viability and Efficacy of its Psoriasis Drug
According to the complaint, the Offering Documents filed in support of Ventyx's October 21, 2021 ...